Combination Ibrutinib and Venetoclax for the Treatment of MCL: Primary End Point Assessment of the Phase 2 AIM Study
Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL
COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor
This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor.
Tolerability and Activity of the Chemotherapy-Free Triplet TGR-1202, Ublituximab, and Ibrutinib in Patients with Advanced CLL and NHL
Randomized, Double-Blind Phase 3 Study of Ibrutinib versus Placebo in Combination with Corticosteroids in Patients with New-Onset cGVHD
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Page 8 of 14
Results 71 - 80 of 134
Results 71 - 80 of 134